Suggested Remit: To appraise the clinical and cost effectiveness of ibalizumab within its marketing authorisation for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen.
Status Proposed
Process STA 2018
ID number 2720

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
03 August 2020 (10:00) Scoping workshop
17 June 2020 - 15 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance